Mabion SA holds FDA meeting on MabionCD20 development for ITP

Mabion SA held a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the development program for MabionCD20, aimed at treating immune thrombocytopenia (ITP). The meeting covered product development strategy, CMC, clinical data, and the regulatory pathway. The company expects the official FDA meeting summary within 30 days.